Home World News Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as... World News Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 979 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Latest episode of our podcast for researchers May 23, 2022 FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma June 22, 2020 For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge January 8, 2020 Olaparib Maintenance Fails in Platinum Sensitive Advanced Non-Small Cell Lung Cancer March 26, 2021 Load more HOT NEWS Droplet Transmission vs. Airborne… What’s the difference? Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... Does Eating Processed Meat Increase Your Risk for Cancer? Race for Life events are back this autumn
